论文部分内容阅读
用本室制备卵巢癌单克隆抗体COC 183 B_2,按武汉生物制品所治疗用单抗要求;经~(131)I标记,按腹腔及皮下注射,分别应用于13例患者。腹腔注射组中,8例显像情况与手术所见完全符合。3例原发卵巢癌均显像,1例Krukenberg瘤转移卵巢不显像,另4例不显像者均为良性肿瘤;皮下注射组中只1例卵巢粘液性囊腺癌术后化疗后锁骨上淋巴结转移未显像,而瘤组织与COC 183 B_2免疫组化染色亦阴性。T/NT比值5.35～13.7,提示此单抗可用作放免显像、肿瘤定位,鉴别诊断、临床分期及追踪检测等。
The ovarian cancer monoclonal antibody COC 183 B_2 was prepared in our laboratory. According to the monoclonal antibody for treatment of biological products in Wuhan, 13 patients were treated with 131I I by intraperitoneal and subcutaneous injection respectively. Intraperitoneal injection group, 8 cases of imaging and surgical findings in full compliance. 3 cases of primary ovarian cancer were imaging, 1 case of Krukenberg metastasis of ovary not imaging, the other 4 cases were not imaging were benign tumors; subcutaneous injection group only 1 case of ovarian mucinous cystadenocarcinoma postoperative chemotherapy after the collarbone The upper lymph node metastasis was not seen, while the tumor tissue and COC 183 B 2 immunohistochemical staining was also negative. T / NT ratio of 5.35 ~ 13.7, suggesting that this monoclonal antibody can be used for radioimmunoimaging, tumor localization, differential diagnosis, clinical staging and tracking tests.